Clinical Trial

Left Atrial Volume Changes Who Underwent Cardioversion and Recurrence of AF After RF Ablation in Persistent AF (SAFE-AF)

Study acronym: SAFE-AF-ABL
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 26, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Electrical/pharmacological cardioversion improves structural remodeling of left atrium. We hypothesize that persistent atrial fibrillation (AF) patients with more significant left atrial size reduction after cardioversion have lower AF recurrence rates following radiofrequency ablation. The aim is to evaluate the relationship between changes in left atrial size 3 to 6 months after cardioversion and the recurrence rate of atrial fibrillation following radiofrequency ablation.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06523738
Lead Sponsor The Second Affiliated Hospital of Chongqing Medical University
Conditions Persisent Atrial Fibrillation, Reversal of Atrial Enlargement, Recurrence of Atrial Fibrillation
Enrollment 100 participants
Start Date 2019-07-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-26